Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

Item

http://www.wikidata.org/entity/Q36402095

Q36402095

about

The EMPA-REG outcome study: critical appraisal and potential clinical implications Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

P2860

Q26748742-AE98FBE6-0CC5-425C-9084-49AA24A310DC Q31105792-AD2FDB7F-FCEC-46BC-AC5D-B5471FF72AC4 Q33890770-4C1B8D14-896F-4893-BCBC-57FFC9574A14 Q36341246-48E5D36D-2183-4C2D-86CF-B1429467AFB4 Q37620904-0BE89730-0912-43CB-9860-FF640A05CED0 Q37721942-E53891D5-F239-4D28-91A1-4F539EB15229 Q38863649-C1C9DD6D-8C76-4C04-ACEF-CA7102D0BF2D Q38866310-4688F981-D715-4B0D-B756-36019AC14812 Q39006105-6A38FDD6-48DF-4F1E-81AA-73C102F0830D Q39039079-43D076A0-2F2D-4DB3-AB75-33F766562D3F Q39290337-10AE77FD-CF7B-4710-A28F-98E732D64F99 Q39401928-0302A3FF-6E6E-498C-9518-83A7E21457AE Q41849079-D3581F30-2801-476D-97F0-B2C91B67183B Q47236288-9268249C-27B3-455A-A935-6EEE292975FF Q47386188-5ED74A65-8746-41B0-9F2D-F75F59EB6141 Q48189020-C4255F63-7315-49C1-814F-05E281EC5236 Q48235609-8983EDE9-3974-48FF-9A49-F18A1B825AEB Q52663367-AAAEDE11-271A-48C8-9C89-D653D5B34E7E

P2860

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

Item

http://www.wikidata.org/entity/Q36402095

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Safety, tolerability and effec ...... I randomized controlled trial.

@ast

Safety, tolerability and effec ...... I randomized controlled trial.

@en

type

Item

label

Safety, tolerability and effec ...... I randomized controlled trial.

@ast

Safety, tolerability and effec ...... I randomized controlled trial.

@en

prefLabel

Safety, tolerability and effec ...... I randomized controlled trial.

@ast

Safety, tolerability and effec ...... I randomized controlled trial.

@en

P1476

Safety, tolerability and effec ...... I randomized controlled trial.

@en

P2093

Afshin Salsali

http://www.w3.org/2001/XMLSchema#string

Anita Vedel Christiansen

http://www.w3.org/2001/XMLSchema#string

EMPA-REG EXTEND™ MONO investigators

http://www.w3.org/2001/XMLSchema#string

Flavien Roux

http://www.w3.org/2001/XMLSchema#string

Gabriel Kim

http://www.w3.org/2001/XMLSchema#string

Hans J Woerle

http://www.w3.org/2001/XMLSchema#string

Ludwig Merker

http://www.w3.org/2001/XMLSchema#string

Michael Roden

http://www.w3.org/2001/XMLSchema#string

Peter Stella

http://www.w3.org/2001/XMLSchema#string

Uli C Broedl

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

SGLT2 inhibitors in the treatment of type 2 diabetes.

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.

The role of empagliflozin in the management of type 2 diabetes by patient profile.

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

P2888

s12933-015-0314-0

P304

154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12933-015-0314-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288002270

http://www.w3.org/2001/XMLSchema#string

P6179

1017003964

http://www.w3.org/2001/XMLSchema#string

P698

26701110

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

phase III clinical trial

P932

4690334

http://www.w3.org/2001/XMLSchema#string

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

about

P2860

P2860

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932